Tailored immunotherapy for HPV positive head and neck squamous cell cancer

Oral Oncology

Volumn 50, Issue 9, 2014, Pages 780-784

  Gildener Leapman, Neil ^a   Lee, John ^b   Ferris, Robert L ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Sanford Ear Nose and Throat Clinic ^*  (United States)

Author keywords

Head and neck squamous cell cancer; Human papilloma virus; Immunotherapy; Vaccine

Indexed keywords

BACTERIAL VECTOR; CYTOKINE; DENDRITIC CELL VACCINE; DNA VACCINE; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; PEPTIDE VACCINE; STAT1 PROTEIN; TUMOR CELL VACCINE; VIRUS VECTOR; CANCER VACCINE;

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IMMUNE RESPONSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WART VIRUS; ALPHAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMAN; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; VIROLOGY;

ALPHAPAPILLOMAVIRUS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY;

EID: 84905925199     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.09.010     Document Type: Article

References (43)

1. A. Psyrri, E. Boutati, and S. Karageorgopoulou Human papillomavirus in head and neck cancers: biology, prognosis, hope of treatment, and vaccines Anti-Cancer Drugs 22 7 Aug 2011 586 590
2. I. Bourgault Villada, M. Moyal Barracco, and M. Ziol et al. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses Cancer Res 64 23 2004 8761 8766
3. S.H. van der Burg Immunotherapy of human papilloma virus induced disease Open Virol J 6 2012 257 263
4. A. Albers, K. Abe, and J. Hunt et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck Cancer Res 65 23 2005 11146 11155
5. D.C. Beachler, K.M. Weber, and J.B. Margolick et al. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults Cancer Epidemiol Biomarkers Prevention 21 1 Jan 2012 122 133 [A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology]
6. M.S. Campo, S.V. Graham, and M.S. Cortese et al. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells Virology 407 1 2010 137 142
7. J. Rautava, and S. Syrjanen Biology of human papillomavirus infections in head and neck carcinogenesis Head Neck Pathol 6 Suppl 1 2012 S3 15
8. G.H. Ashrafi, M. Haghshenas, B. Marchetti, and M.S. Campo E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain Int J Cancer 119 9 2006 2105 2112
9. W. Li, X.M. Deng, and C.X. Wang et al. Down-regulation of HLA class I antigen in human papillomavirus type 16 E7 expressing HaCaT cells: correlate with TAP-1 expression Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 20 2 Feb 2010 227 232
10. S.J. Um, J.W. Rhyu, E.J. Kim, K.C. Jeon, E.S. Hwang, and J.S. Park Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo Cancer Lett 179 2 2002 205 212
11. M.S. Leibowitz, R.M. Srivastava, and P.A. Andrade Filho et al. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells Clin Cancer Res Off J Am Assoc Cancer Res 19 4 2013 798 808
12. T. Yoshida, T. Sano, and T. Kanuma et al. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions Cancer 114 2 2008 83 88
13. M.I. van Poelgeest, E.R. Nijhuis, and K.M. Kwappenberg et al. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia Int J Cancer 118 3 2006 675 683
14. M.P. Schon, and M. Schon Imiquimod: mode of action Brit J Dermatol 157 Suppl 2 2007 8 13
15. M. van Seters, M. van Beurden, and F.J. ten Kate et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod N Engl J Med 358 14 2008 1465 1473
16. A. Terlou, M. van Seters, and A. Kleinjan et al. Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia Int J Cancer 127 12 2010 2831 2840
17. S. Daayana, E. Elkord, and U. Winters et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia Br J Cancer 102 7 2010 1129 1136
18. O. Peralta-Zaragoza, V.H. Bermudez-Morales, C. Perez-Plasencia, J. Salazar-Leon, C. Gomez-Ceron, and V. Madrid-Marina Targeted treatments for cervical cancer: a review Oncotargets Ther 5 2012 315 328
19. E. Luedke, A.C. Jaime-Ramirez, and N. Bhave et al. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines Surgery 152 3 2012 431 440
20. S.M. Freeman, J.L. Franco, and D.E. Kenady et al. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck Am J Clin Oncol 34 2 Apr 2011 173 178
21. P. Hubert, J. Doyen, and X. Capelle et al. Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions Am J Reprod Immunol 64 2 2010 126 136
22. K.J. Harrington, M. Hingorani, and M.A. Tanay et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck Clin Cancer Res Off J Am Assoc Cancer Res 16 15 2010 4005 4015
23. J.L. Brun, V. Dalstein, and J. Leveque et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy Am J Obstet Gynecol 204 2 2011 169 [e161-168]
24. EORTC. Transgene Collaborates with EORTC on Phase 2b Trial with TG4001 in Head & Neck Cancer.
25. M.L. Gillison, T. Broutian, and R.K. Pickard et al. Prevalence of oral HPV infection in the United States, 2009-2010 JAMA J Am Med Assoc 307 7 2012 693 703
26. C.J. Voskens, D. Sewell, and R. Hertzano et al. Induction of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma Head Neck 34 12 2012 1734 1746
27. G.G. Kenter, M.J. Welters, and A.R. Valentijn et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia N Engl J Med 361 19 2009 1838 1847
28. P.J. de Vos van Steenwijk, T.H. Ramwadhdoebe, and M.J. Lowik et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions Cancer Immunol Immunother CII 61 9 2012 1485 1492
29. J. Martin Caballero, A. Garzon, and L. Gonzalez-Cintado et al. Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors Plos One 7 12 2012 e52976
30. C.F. Huang, A. Monie, W.H. Weng, and T. Wu DNA vaccines for cervical cancer Am J Transl Res 2 1 2010 75 87
31. E.E. Sheets, R.G. Urban, and C.P. Crum et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle- delivered human papillomavirus 16 E7 plasmid DNA Am J Obstet Gynecol 188 4 Apr 2003 916 926
32. ClinicalTrials.gov. Safety study of HPV DNA vaccine to treat head and neck cancer patients. < http://clinicaltrials.gov/ct2/show/NCT01493154?term= pNGVL4a&rank=1 > [accessed 12.04.13].
33. R. Mikyskova, M. Indrova, J. Simova, J. Bieblova, J. Bubenik, and M. Reinis Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine Oncol Rep 25 6 2011 1683 1689
34. C. Mansilla, P. Berraondo, and M. Durantez et al. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin Int J Cancer 131 3 2012 641 651
35. D.A. Sewell, Z.K. Pan, and Y. Paterson Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors Vaccine 26 41 2008 5315 5320
36. ClinicalTrials.gov. Safety study of recombinant listeria monocytogenes(Lm)based vaccine virus vaccine to treat oropharyngeal cancer (REALISTIC:). < http://www.clinicaltrials.gov/ct2/show/NCT01598792?term= listeria+hpv&rank=1 > [accessed 29.03.13].
37. ClinicalTrials.gov. A randomized, single blind, placebo controlled phase 2 study to assess the safety of ADXS11-001 for the treatment of cervical intraepithelial neoplasia grade 2/3. < http://www.clinicaltrials.gov/ct2/ show/NCT01116245?term=listeria+hpv&rank=2 > [accessed 29.03.13].
38. C.A. Ramos, N. Narala, and G.M. Vyas et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies J Immunother 36 1 2013 66 76
39. R.M. Srivastava, S.C. Lee, and P.A. Andrade Filho et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients Clin Cancer Res Off J Am Assoc Cancer Res 19 7 2013 1858 1872
40. P. Kabolizadeh, G.J. Kubicek, D.E. Heron, R.L. Ferris, and M.K. Gibson The role of cetuximab in the management of head and neck cancers Exp Opin Biol Ther 12 4 Apr 2012 517 528
41. S. Lyford-Pike, S. Peng, and G.D. Young et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma Cancer Res 73 6 2013 1733 1741
42. C. Badoual, S. Hans, and N. Merillon et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer Cancer Res 73 1 2013 128 138
43. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 4 2012 252 264